Business Context and Reporting Period
This Form 6-K filing by Belite Bio, Inc. covers the month of December 2025. The report announces the commencement of an underwritten offering of American Depositary Shares (ADSs), with each ADS representing one ordinary share. The offering is conducted pursuant to the Company's automatic shelf registration statement on Form F-3, which became effective on January 27, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the announcement of a capital raising activity and does not contain financial performance data.
Material Changes
The primary material event is the initiation of an underwritten public offering of ADSs. The filing notes that the offering is subject to market conditions, and there is no assurance regarding the completion, timing, size, or specific terms of the offering.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the offering. The filing explicitly states that the report does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such action would be unlawful prior to registration. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the final terms, size, and pricing of the underwritten ADS offering once completed.
- Confirm whether the offering was successfully closed given the stated market condition contingencies.
- Review the preliminary prospectus supplement dated December 1, 2025, for detailed use of proceeds.
- Check subsequent filings for updated financial metrics not included in this current report.